NSPR Earnings Prediction
The chart below shows how NSPR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NSPR sees a +1.41% change in stock price 10 days leading up to the earnings, and a -3.33% change 10 days following the report. On the earnings day itself, the stock moves by -0.58%. This data can give you a slight idea of what to expect for the next quarter's release.
NSPR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
NSPR Earnings Analysis
InspireMD Inc Corporation (NSPR.O) Earnings Conference Call
Positive
Quarterly Revenue Milestone: CGuard revenue reached a new quarterly high of $1.95 million in Q4 2024, reflecting a 10.6% growth year-over-year.
Revenue Increase Overview: Total revenue for the full year 2024 increased 13% to $7 million from $6.2 million in 2023, driven by growth in existing and new markets.
CGuard Stent Sales Performance: 3,512 CGuard stents were sold in Q4 2024, contributing to a total of 12,100 units sold for the full year, benefiting thousands of patients.
CGuard Prime Launch Anticipation: The company is on track for anticipated US approval and launch of CGuard Prime in the first half of 2025, which is expected to significantly expand revenue.
Clinical Trial Success: The CGUARDIANS pivotal clinical trial showed unprecedented results with major adverse events rates of just 0.95% through 30 days and 1.95% through 12 months post-procedure, the lowest ever reported in a pivotal study of carotid stents.
Sales Team Expansion: The company has onboarded more than a dozen world-class field sales professionals in preparation for the US launch, indicating strong interest and confidence in CGuard Prime.
Financial Income Increase: Increased financial income for the full year 2024 by 20.5% to $1.6 million, primarily due to higher interest income from investments.
Strategic Headquarters Location: The new headquarters in Miami, Florida, is strategically positioned to support the anticipated US launch and commercialization of CGuard Prime.
Negative
Gross Profit Decline: Gross profit for Q4 2024 decreased by $36,000 or 7.1% to $469,000 compared to Q4 2023, due to increased cost of goods sold.
Gross Margin Decline: Gross margin decreased to 24.1% in Q4 2024 from 28.7% in Q4 2023, attributed to higher material and labor costs.
Operating Expenses Surge: Total operating expenses for Q4 2024 increased by $3.5 million or 55.8% to $9.8 million compared to Q4 2023, primarily due to increased salaries and share-based compensation.
Quarterly Net Loss Comparison: Net loss for Q4 2024 totaled $9.1 million or $0.19 per share, compared to a net loss of $5.4 million or $0.16 per share in Q4 2023.
Gross Profit Decline: Gross profit for the full year 2024 decreased by $301,000 or 16.7% to $1.5 million compared to 2023, again due to increased cost of goods sold.
Gross Margin Decline: Gross margin for the full year 2024 decreased to 21.5% from 29.1% in 2023, reflecting ongoing cost pressures.
Operating Expenses Increase: Total operating expenses for the full year 2024 were $35 million, an increase of $12 million or 52.5% compared to 2023, driven by higher salaries and compensation costs.
Annual Net Loss Comparison: Net loss for the full year 2024 was $32 million or $0.76 per share, compared to a net loss of $19.9 million or $0.82 per share in 2023.
Cash Decrease Analysis: Cash and cash equivalents decreased to $34.7 million as of December 31, 2024, down from $39 million at the end of 2023.
NSPR FAQs
How does NSPR typically perform around its earnings report dates?
Is InspireMD Inc (NSPR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NSPR Earning Call Sentiment
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
NSPR.O
0.72%Positive
The earnings call reveals several negative factors: increased net loss, declining gross margins, and rising operational costs. Despite revenue growth, the financial health appears strained. The lack of shareholder return plans and vague management responses in the Q&A add to concerns. Furthermore, the dependency on US market approval, which is uncertain, introduces significant risk. While there are growth opportunities, the current financial challenges and uncertainties outweigh the positives, leading to a negative sentiment overall.
